Bayer: enrolls first US patient in phase III trials.
(CercleFinance.com) - Bayer has announced that a first US patient has been enrolled in a Phase III clinical trial for vilaprisan, a treatment for women with symptomatic uterine fibroids.
Bayer - which reminds it has a rich legacy in women's health research - says the trial reinforces its ongoing commitment to "finding innovative solutions for women suffering from gynecological conditions."
The drug treats the most common benign uterine tumors in women of reproductive age; it is estimated between 70% and 80% of American women may develop uterine fibroids by age 50.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Bayer - which reminds it has a rich legacy in women's health research - says the trial reinforces its ongoing commitment to "finding innovative solutions for women suffering from gynecological conditions."
The drug treats the most common benign uterine tumors in women of reproductive age; it is estimated between 70% and 80% of American women may develop uterine fibroids by age 50.
Copyright (c) 2017 CercleFinance.com. All rights reserved.